Yao-Jun Zhang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1608522/publications.pdf

Version: 2024-02-01

		87723	102304
137	5,184	38	66
papers	citations	h-index	g-index

146	146	146	5792
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Quantification of Incomplete Revascularization and its Association With Five-Year Mortality in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Trial Validation of the Residual SYNTAX Score. Circulation, 2013, 128, 141-151.	1.6	326
2	The Negative Impact of Incomplete Angiographic Revascularization on Clinical Outcomes and Its Association With Total Occlusions. Journal of the American College of Cardiology, 2013, 61, 282-294.	1.2	257
3	Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials. Heart, 2014, 100, 1158-1164.	1.2	216
4	Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial. Lancet, The, 2021, 398, 2149-2159.	6.3	175
5	Optimal Medical Therapy Improves Clinical Outcomes in Patients Undergoing Revascularization With Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting. Circulation, 2015, 131, 1269-1277.	1.6	167
6	Comparison of intravascular ultrasound versus angiography-guided drug-eluting stent implantation: a meta-analysis of one randomised trial and ten observational studies involving 19,619 patients. EuroIntervention, 2012, 8, 855-865.	1.4	163
7	Impact of the Complexity of Bifurcation Lesions Treated With Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2014, 7, 1266-1276.	1.1	153
8	Cancerâ€Associated Fibroblastâ€Mediated Cellular Crosstalk Supports Hepatocellular Carcinoma Progression. Hepatology, 2021, 73, 1717-1735.	3.6	147
9	Angiographic and clinical comparisons of intravascular ultrasound- versus angiography-guided drug-eluting stent implantation for patients with chronic total occlusion lesions: two-year results from a randomised AIR-CTO study. EuroIntervention, 2015, 10, 1409-1417.	1.4	139
10	Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. Journal of Clinical Oncology, 2022, 40, 150-160.	0.8	137
11	Berberine improves pressure overload-induced cardiac hypertrophy and dysfunction through enhanced autophagy. European Journal of Pharmacology, 2014, 728, 67-76.	1.7	128
12	Bioresorbable Drug-Eluting Magnesium-Alloy Scaffold for Treatment of Coronary Artery Disease. International Journal of Molecular Sciences, 2013, 14, 24492-24500.	1.8	109
13	Effect of the Endothelial Shear Stress Patterns on Neointimal Proliferation Following Drug-Eluting Bioresorbable Vascular Scaffold Implantation. JACC: Cardiovascular Interventions, 2014, 7, 315-324.	1.1	108
14	Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Journal of Hepatology, 2015, 63, 122-130.	1.8	101
15	Smoking Is Associated With Adverse Clinical Outcomes in PatientsÂUndergoing Revascularization With PCI or CABG. Journal of the American College of Cardiology, 2015, 65, 1107-1115.	1.2	99
16	Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapyversuslenvatinib alone for advanced hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110027.	1.4	91
17	Intracoronary Optical Coherence Tomography and Histology of Overlapping Everolimus-Eluting Bioresorbable Vascular Scaffolds in a Porcine Coronary Artery Model. JACC: Cardiovascular Interventions, 2013, 6, 523-532.	1.1	84
18	Comparison of intravascular ultrasound guided versus angiography guided drug eluting stent implantation: a systematic review and meta-analysis. BMC Cardiovascular Disorders, 2015, 15, 153.	0.7	81

#	Article	IF	Citations
19	Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivo. EuroIntervention, 2013, 9, 269-276.	1.4	80
20	Intravascular ultrasound-guided drug-eluting stent implantation: An updated meta-analysis of randomized control trials and observational studies. International Journal of Cardiology, 2016, 216, 133-139.	0.8	73
21	Feasibility of using deep learning to detect coronary artery disease based on facial photo. European Heart Journal, 2020, 41, 4400-4411.	1.0	67
22	Stenting strategy for coronary artery bifurcation with drug-eluting stents: a meta-analysis of nine randomised trials and systematic review. EuroIntervention, 2014, 10, 561-569.	1.4	66
23	Predictive Performance of SYNTAX Score II in Patients With Left Main and Multivessel Coronary Artery Disease. Circulation Journal, 2014, 78, 1942-1949.	0.7	64
24	Short-Term and Long-Term Clinical Impact of Stent Thrombosis and Graft Occlusion in the SYNTAX Trial at 5 Years. Journal of the American College of Cardiology, 2013, 62, 2360-2369.	1.2	62
25	Vessels That Encapsulate Tumor Clusters (VETC) Pattern Is a Predictor of Sorafenib Benefit in Patients with Hepatocellular Carcinoma. Hepatology, 2019, 70, 824-839.	3.6	62
26	The Ginsenoside Rg1 Prevents Transverse Aortic Constrictionâ€“Induced Left Ventricular Hypertrophy and Cardiac Dysfunction by Inhibiting Fibrosis and Enhancing Angiogenesis. Journal of Cardiovascular Pharmacology, 2013, 62, 50-57.	0.8	60
27	Assessing Bioresorbable Coronary Devices. JACC: Cardiovascular Imaging, 2014, 7, 1130-1148.	2.3	60
28	A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial. EuroIntervention, 2013, 9, 75-83.	1.4	60
29	Berberine attenuates adverse left ventricular remodeling and cardiac dysfunction after acute myocardial infarction in rats: Role of autophagy. Clinical and Experimental Pharmacology and Physiology, 2014, 41, 995-1002.	0.9	59
30	Bioresorbable scaffolds: Current knowledge, potentialities and limitations experienced during their first clinical applications. International Journal of Cardiology, 2013, 167, 11-21.	0.8	56
31	A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. OncoImmunology, 2016, 5, e1083671.	2.1	56
32	Macrophages induce CD47 upregulation via IL-6 and correlate with poor survival in hepatocellular carcinoma patients. OncoImmunology, 2019, 8, e1652540.	2.1	55
33	TACC3 promotes stemness and is a potential therapeutic target in hepatocellular carcinoma. Oncotarget, 2015, 6, 24163-24177.	0.8	54
34	Predicting 3-Year Mortality After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 464-470.	1.1	50
35	Prognostic Value of Site SYNTAX Score and Rationale for Combining Anatomic and Clinical Factors in Decision Making. Journal of the American College of Cardiology, 2014, 64, 423-432.	1.2	48
36	Comparison of one-year clinical outcomes between intravascular ultrasound-guided versus angiography-guided implantation of drug-eluting stents for left main lesions: a single-center analysis of a 1,016-patient cohort. Patient Preference and Adherence, 2014, 8, 1299.	0.8	43

#	Article	IF	Citations
37	Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data. EuroIntervention, 2015, 11, 746-756.	1.4	42
38	Five-year clinical follow-up of unprotected left main bifurcation lesion stenting: one-stent versus two-stent techniques versus double-kissing crush technique. EuroIntervention, 2012, 8, 803-814.	1.4	40
39	Fusion of optical coherence tomographic and angiographic data for more accurate evaluation of the endothelial shear stress patterns and neointimal distribution after bioresorbable scaffold implantation: comparison with intravascular ultrasound-derived reconstructions. International Journal of Cardiovascular Imaging, 2014, 30, 485-494.	0.7	37
40	Prospective, single-center cohort study analyzing the efficacy of complete laparoscopic resection on recurrent hepatocellular carcinoma. Chinese Journal of Cancer, 2016, 35, 25.	4.9	37
41	Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial. Heart, 2013, 99, 1267-1274.	1.2	36
42	Tumor Location Influences Oncologic Outcomes of Hepatocellular Carcinoma Patients Undergoing Radiofrequency Ablation. Cancers, 2018, 10, 378.	1.7	36
43	Mesenchymal stem cells with overexpression of midkine enhance cell survival and attenuate cardiac dysfunction in a rat model of myocardial infarction. Stem Cell Research and Therapy, 2014, 5, 37.	2.4	35
44	Progress in Treatment by Percutaneous Coronary Intervention: The Stent of the Future. Revista Espanola De Cardiologia (English Ed), 2013, 66, 483-496.	0.4	34
45	Early (before 6 months), late (6-12 months) and very late (after 12 months) angiographic scaffold restenosis in the ABSORB Cohort B trial. EuroIntervention, 2015, 10, 1288-1298.	1.4	34
46	Bioresorbable Scaffolds: Current Evidence and Ongoing Clinical Trials. Current Cardiology Reports, 2012, 14, 626-634.	1.3	33
47	A nomogram predicting the recurrence of hepatocellular carcinoma in patients after laparoscopic hepatectomy. Cancer Communications, 2019, 39, 1-11.	3.7	33
48	Prognostic implications of severe coronary calcification in patients undergoing coronary artery bypass surgery: An analysis of the SYNTAX Study. Catheterization and Cardiovascular Interventions, 2015, 85, 199-206.	0.7	32
49	Derived neutrophil to lymphocyte ratio predicts prognosis for patients with HBV-associated hepatocellular carcinoma following transarterial chemoembolization. Oncology Letters, 2016, 11, 2987-2994.	0.8	30
50	Comparison of acute gain and late lumen loss after PCI with bioresorbable vascular scaffolds versus everolimus-eluting stents: an exploratory observational study prior to a randomised trial. EuroIntervention, 2014, 10, 672-680.	1.4	30
51	Left atrial appendage closure monitoring without sedation: a pilot study using intracardiac echocardiography through the oesophageal route. EuroIntervention, 2015, 11, 936-941.	1.4	29
52	Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients. BMC Cancer, 2021, 21, 775.	1.1	28
53	Vulnerable plaque detection: an unrealistic quest or a feasible objective with a clinical value?. Heart, 2016, 102, 581-589.	1.2	27
54	Noninvasive Prediction of Atherosclerotic Progression: The PROSPECT-MSCT Study. JACC: Cardiovascular Imaging, 2016, 9, 1009-1011.	2.3	27

#	Article	IF	Citations
55	The Anatomic- and Clinical-Based NERS (New Risk Stratification) Score II to Predict Clinical Outcomes After Stenting Unprotected Left Main Coronary Artery Disease. JACC: Cardiovascular Interventions, 2013, 6, 1233-1241.	1.1	24
56	Scaffold and Edge Vascular Response Following Implantation of Everolimus-Eluting Bioresorbable Vascular Scaffold. JACC: Cardiovascular Interventions, 2014, 7, 1361-1369.	1.1	23
57	Radiofrequency ablation versus laparoscopic hepatectomy for hepatocellular carcinoma: A real world single center study. European Journal of Surgical Oncology, 2020, 46, 548-559.	0.5	23
58	Stereotactic Body Radiotherapy vs. Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma: A Meta-Analysis. Frontiers in Oncology, 2020, 10, 1639.	1.3	22
59	Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis. Cancer Immunology, Immunotherapy, 2021, 70, 3207-3216.	2.0	21
60	Circumferential distribution of the neointima at six-month and two-year follow-up after a bioresorbable vascular scaffold implantation: a substudy of the ABSORB Cohort B Clinical Trial. EuroIntervention, 2015, 10, 1299-1306.	1.4	20
61	Comparison of Stable and Unstable Ethiodized Oil Emulsions for Transarterial Chemoembolization of Hepatocellular Carcinoma:ÂResults of a Single-Center Double-BlindÂProspective Randomized ControlledÂTrial. Journal of Vascular and Interventional Radiology, 2018, 29, 1068-1077.e2.	0.2	19
62	Optical coherence tomography enables more accurate detection of functionally significant intermediate non-left main coronary artery stenoses than intravascular ultrasound: A meta-analysis of 6919 patients and 7537 lesions. International Journal of Cardiology, 2020, 301, 226-234.	0.8	19
63	Development and validation of prognostic nomograms for single large and huge hepatocellular carcinoma after curative resection. European Journal of Cancer, 2021, 155, 85-96.	1.3	19
64	Bioresorbable scaffolds in the treatment of coronary artery disease. Medical Devices: Evidence and Research, 2013, 6, 37.	0.4	17
65	Impact of oral antiâ€“hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization. Chinese Journal of Cancer, 2015, 34, 205-16.	4.9	17
66	Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Propensity Score Matching Study. Cancers, 2019, 11, 1116.	1.7	17
67	In vivo assessment of the three-dimensional haemodynamic micro-environment following drug-eluting bioresorbable vascular scaffold implantation in a human coronary artery: fusion of frequency domain optical coherence tomography and angiography. EuroIntervention, 2013, 9, 890-890.	1.4	17
68	Implications of the local hemodynamic forces on the formation and destabilization of neoatherosclerotic lesions. International Journal of Cardiology, 2018, 272, 7-12.	0.8	16
69	Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients. Cancer Communications, 2020, 40, 355-369.	3.7	16
70	Clinical and multimodality imaging results at 6 months of a bioresorbable sirolimus-eluting scaffold for patients with single de novo coronary artery lesions: the NeoVas first-in-man trial. EuroIntervention, 2016, 12, 1279-1287.	1.4	16
71	Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection. Journal of Gastroenterology, 2022, 57, 185-198.	2.3	16
72	The impact of everolimus versus other rapamycin derivative-eluting stents on clinical outcomes in patients with coronary artery disease: A meta-analysis of 16 randomized trials. Journal of Cardiology, 2014, 64, 185-193.	0.8	15

#	Article	IF	Citations
73	Biolimus-eluting stent with biodegradable polymer improves clinical outcomes in patients with acute myocardial infarction. Heart, 2015, 101, 271-278.	1.2	15
74	Invasive or non-invasive imaging for detecting high-risk coronary lesions?. Expert Review of Cardiovascular Therapy, 2017, 15, 165-179.	0.6	15
75	Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Stage B1 Intermediate Hepatocellular Carcinoma. Journal of Oncology, 2019, 2019, 1-7.	0.6	15
76	Evaluation of vascular healing of polymer-free sirolimus-eluting stents in native coronary artery stenosis: a serial follow-up at three and six months with optical coherence tomography imaging. EuroIntervention, 2016, 12, e574-e583.	1.4	15
77	Periprocedural myocardial infarction is associated with increased mortality in patients with coronary artery bifurcation lesions after implantation of a drugâ€eluting stent. Catheterization and Cardiovascular Interventions, 2015, 85, 696-705.	0.7	14
78	Expression of Pim-3 in colorectal cancer and its relationship with prognosis. Tumor Biology, 2016, 37, 9151-9156.	0.8	14
79	Comparison of new-generation drug-eluting stents versus drug-coated balloon for in-stent restenosis: a meta-analysis of randomised controlled trials. BMJ Open, 2018, 8, e017231.	0.8	14
80	Sorafenib Monotherapy Versus Sorafenib Combined with Regional Therapies for Hepatocellular Carcinoma Patients with Pulmonary Oligometastases: A Propensity Score-matched Analysis. Journal of Cancer, 2018, 9, 1745-1753.	1.2	14
81	Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Sorafenib as Initial Treatment for Advanced Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 619461.	1.3	14
82	Nine-month angiographic and two-year clinical follow-up of polymer-free sirolimus-eluting stent versus durable-polymer sirolimus-eluting stent for coronary artery disease: the Nano randomized trial. Chinese Medical Journal, 2014, 127, 2153-8.	0.9	14
83	Assessing Hepatic Fibrosis Using 2-D Shear Wave Elastography in Patients with Liver Tumors: A Prospective Single-Center Study. Ultrasound in Medicine and Biology, 2017, 43, 2522-2529.	0.7	13
84	12-Month clinical results of drug-coated balloons for de novo coronary lesion in vessels exceeding 3.0Âmm. International Journal of Cardiovascular Imaging, 2019, 35, 579-586.	0.7	13
85	Neointima and neoatherosclerotic characteristics in bare metal and first- and second-generation drug-eluting stents in patients admitted with cardiovascular events attributed to stent failure: an optical coherence tomography study. EuroIntervention, 2018, 13, e1831-e1840.	1.4	13
86	Temporal Evolution of Strut Light Intensity After Implantation of Bioresorbable Polymeric Intracoronary Scaffolds in the ABSORB Cohort B Trial. Circulation Journal, 2014, 78, 1873-1881.	0.7	12
87	Prognostic Values of Alpha-Fetoprotein and Des-Gamma-Carboxyprothrombin in Hepatocellular Carcinoma in China: An Analysis of 4792 Patients. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 657-670.	1.8	12
88	Short- and Long-Term Implications of a Bioresorbable Vascular Scaffold Implantation on the Local Endothelial Shear Stress Patterns. JACC: Cardiovascular Interventions, 2014, 7, 100-101.	1.1	11
89	Angioscopy study from a large patient population comparing sirolimusâ€eluting stent with biodegradable versus durable polymer. Catheterization and Cardiovascular Interventions, 2012, 80, 420-428.	0.7	10
90	Intimal Flaps Detected by Optical Frequency Domain Imaging in the Proximal Segments of Native Coronary Arteries. Circulation Journal, 2013, 77, 2327-2333.	0.7	10

#	Article	IF	Citations
91	Long-term therapy with sorafenib is associated with pancreatic atrophy. Journal of Surgical Research, 2015, 199, 314-321.	0.8	10
92	Intention to control low central venous pressure reduced blood loss during laparoscopic hepatectomy: A double-blind randomized clinical trial. Surgery, 2020, 167, 933-941.	1.0	10
93	Impact of body mass index on longâ€term clinical outcomes after secondâ€generation drug eluting stent implantation: Insights from the international global <scp>RESOLUTE</scp> program. Catheterization and Cardiovascular Interventions, 2015, 85, 952-958.	0.7	9
94	A head to head comparison of XINSORB bioresorbable sirolimus-eluting scaffold versus metallic sirolimus-eluting stent: 180 days follow-up in a porcine model. International Journal of Cardiovascular Imaging, 2017, 33, 1473-1481.	0.7	9
95	Predictive factors for the benefit of tripleâ€drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma. Cancer Medicine, 2019, 8, 4200-4213.	1.3	9
96	Development and Validation of a Prognostic Score for Hepatocellular Carcinoma Patients in Immune Checkpoint Inhibitors Therapies: The Hepatocellular Carcinoma Modified Gustave Roussy Immune Score. Frontiers in Pharmacology, 2021, 12, 819985.	1.6	9
97	Oneâ€year clinical results of the NANO registry: A multicenter, prospective allâ€comers registry study in patients receiving implantation of a polymerâ€free sirolimusâ€eluting stent. Catheterization and Cardiovascular Interventions, 2020, 95, 658-664.	0.7	8
98	Assessment of plaque evolution in coronary bifurcations located beyond everolimus eluting scaffolds: serial intravascular ultrasound virtual histology study. Cardiovascular Ultrasound, 2013, 11, 25.	0.5	7
99	Bioresorbable vascular scaffolds in the clinical setting. Interventional Cardiology, 2013, 5, 639-646.	0.0	7
100	Comparison of long-term in-stent vascular response between abluminal groove-filled biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent: 3-year OCT follow-up from the TARGET I trial. International Journal of Cardiovascular Imaging, 2015, 31, 1489-1496.	0.7	7
101	Robot-assisted laparoscopic partial hepatic caudate lobectomy. Minimally Invasive Therapy and Allied Technologies, 2019, 28, 292-297.	0.6	7
102	Revisiting: â€œComparison of intravascular ultrasound versus angiography-guided drug-eluting stent implantation: a meta-analysis of one randomised trial and ten observational studies involving 19,619 patientsâ€• EuroIntervention, 2013, 9, 891-892.	1.4	7
103	Left jackknife position: a novel position for laparoscopic hepatectomy. Chinese Journal of Cancer, 2017, 36, 31.	4.9	6
104	Oneâ€year clinical outcomes and multislice computed tomography angiographic results following implantation of the <scp>N</scp>eo<scp>V</scp>as bioresorbable sirolimusâ€eluting scaffold in patients with single de novo coronary artery lesions. Catheterization and Cardiovascular Interventions, 2018, 91, 617-622.	0.7	6
105	Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Cohort Study. Journal of Oncology, 2020, 2020, 1-9.	0.6	6
106	Baseline HBV Loads Do Not Affect the Prognosis of Patients with Hepatocellular Carcinoma Receiving Anti-Programmed Cell Death-1 Immunotherapy . Journal of Hepatocellular Carcinoma, 2020, Volume 7, 337-345.	1.8	6
107	Comparative safety and efficacy of molecular-targeted drugs, immune checkpoint inhibitors, hepatic arterial infusion chemotherapy and their combinations in advanced hepatocellular carcinoma: findings from advances in landmark trials. Frontiers in Bioscience, 2021, 26, 873.	0.8	6
108	Intravascular Ultrasound Classification of Plaque in Angiographic True Bifurcation Lesions of the Left Main Coronary Artery. Chinese Medical Journal, 2016, 129, 1538-1543.	0.9	5

#	Article	IF	Citations
109	Comparison between twoâ€dimensional and threeâ€dimensional quantitative coronary angiography for the prediction of functional severity in true bifurcation lesions: Insights from the randomized DKâ€CRUSH II, III, and IV trials. Catheterization and Cardiovascular Interventions, 2016, 87, 589-598.	0.7	5
110	The Optimal Management for Sub-Centimeter Hepatocellular Carcinoma: Curative Treatments or Follow-Up?. Medical Science Monitor, 2019, 25, 4941-4951.	0.5	5
111	Can Immediately Treating Subcentimeter Hepatocellular Carcinoma Improve the Survival of Patients? . Journal of Hepatocellular Carcinoma, 2020, Volume 7, 377-384.	1.8	5
112	Impact of biodegradable versus durable polymer drug-eluting stents on clinical outcomes in patients with coronary artery disease: a meta-analysis of 15 randomized trials. Chinese Medical Journal, 2014, 127, 2159-66.	0.9	5
113	Acute Effects of Nicardipine and Esmolol on The Cardiac Cycle, Intracardiac Hemodynamic and Endothelial Shear Stress in Patients With Unstable Angina Pectoris and Moderate Coronary Stenosis: Results From Single Center, Randomized Study. Cardiovascular Therapeutics, 2012, 30, 162-171.	1.1	4
114	Parecoxib prevents complications in hepatocellular carcinoma patients receiving hepatic transarterial chemoembolization: a prospective score-matched cohort study. Oncotarget, 2016, 7, 27938-27945.	0.8	4
115	Implications of a bioresorbable vascular scaffold implantation on vessel wall strain of the treated and the adjacent segments. International Journal of Cardiovascular Imaging, 2014, 30, 477-484.	0.7	3
116	Clinical Impact of Dual Antiplatelet Therapy Use in Patients Following Everolimus-eluting Stent Implantation. Chinese Medical Journal, 2015, 128, 714-720.	0.9	3
117	Intravascular imaging in cardiovascular ageing. Experimental Gerontology, 2018, 109, 31-37.	1.2	3
118	Single versus multiple port laparoscopic left lateral sectionectomy for hepatocellular carcinoma: A retrospective comparative study. International Journal of Surgery, 2020, 77, 15-21.	1.1	3
119	Clinical outcomes of â€œcomplete, partially complete, and incompleteâ€•revascularisation at five-year follow-up after percutaneous intervention of unprotected left main coronary artery disease with drug-eluting stents. EuroIntervention, 2016, 12, e957-e963.	1.4	3
120	NOBORIâ„¢ biodegradable-polymer biolimus-eluting stent versus durable-polymer drug-eluting stents: A meta-analysis. International Journal of Cardiology, 2014, 174, 151-153.	0.8	2
121	Use of sodium nitroprusside in retrograde percutaneous coronary intervention for chronic total occlusion. Medicine (United States), 2018, 97, e11498.	0.4	2
122	Biodegradable or biocompatible polymer drug-eluting stent: a Gordian knot. EuroIntervention, 2015, 11, 250-252.	1.4	2
123	Drug-coated balloon combined with provisional drug-eluting stent implantation for the treatment of de novo Medina 0,1,0 or 0,0,1 left main coronary bifurcation lesions: A proof-ofconcept study. , 2022, 26, 218-225.		2
124	TCT-837 Everolimus-eluting versus other rapamycin derivatives-eluting stents in patients with coronary artery disease: a meta-analysis of 16 randomized trials. Journal of the American College of Cardiology, 2013, 62, B253.	1.2	1
125	Response to Letter Regarding Article, â€œQuantification of Incomplete Revascularization and Its Association With Five-Year Mortality in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Trial: Validation of the Residual SYNTAX Scoreâ€• Circulation, 2014, 129, e355-6.	1.6	1
126	The impact of dual antiplatelet therapy duration on primary composite endpoint after drug-eluting stent implantation: A meta-analysis of 10 randomized trials. International Journal of Cardiology, 2016, 202, 504-506.	0.8	1

#	Article	IF	Citations
127	Optical coherence tomography assessment of a complex bifurcation lesion treated with double kissing Crush technique. Medicine (United States), 2017, 96, e5740.	0.4	1
128	Effect of prior cancer on survival of hepatocellular carcinoma: implications for clinical trial eligibility criteria. BMC Cancer, 2021, 21, 147.	1.1	1
129	Pulmonary arterial hypertension: pharmacologic therapies and potential pulmonary artery denervation treatment. EuroIntervention, 2013, 9, R149-R154.	1.4	1
130	Clinical outcomes in 2481 unselected real-world patients treated with a polymer-free sirolimus-eluting stent: 3Âyears results from the NANO multicenter Registry. BMC Cardiovascular Disorders, 2021, 21, 537.	0.7	1
131	Bioresorbable scaffolds for coronary artery disease: current status and future prospective. Chinese Medical Journal, 2014, 127, 1141-8.	0.9	1
132	TCT-78 Long-Term (4-Year) Clinical Outcomes of Total Occlusions and Completeness of Revascularisation in the Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery Trial. Journal of the American College of Cardiology, 2012, 60, B25.	1.2	0
133	TCT-246 Comparison of intravascular ultrasound versus angiography guided drug-eluting stent implantation: a meta-analysis of randomized trials and observational studies involving 17,570 patients. Journal of the American College of Cardiology, 2012, 60, B70.	1.2	0
134	Radial approach for patients with ST-segment elevation acute coronary syndrome: It is definitely the best access site. International Journal of Cardiology, 2013, 168, 3140-3142.	0.8	0
135	Comparison of Intravascular Ultrasound Versus Angiography Guided Drug-eluting Stent Implantation: A Meta-analysis of Randomized Trials and Observational Studies Involving 28,745 Patients. American Journal of Cardiology, 2013, 111, 41B.	0.7	0
136	68â€...Predicting 3-Year Mortality After PCI: Revised Clinical Syntax Model Based on Patient Level Data from 7 Contemporary Stent Trials. Heart, 2014, 100, A38.2-A39.	1.2	0
137	Optimal subsequent treatments for patients with hepatocellular carcinoma resistant to anti-PD-1 treatment. Immunotherapy, 2021, , .	1.0	0